Outcomes of Arterial Bypass With the Human Acellular Vessel for Chronic Limb-Threatening Ischemia Performed Under the FDA Expanded Access Program
To report outcomes of the human acellular vessel (HAV) implanted for limb salvage through the Food and Drug Administration (FDA) Expanded Access Program for patients with chronic limb-threatening ischemia with no autologous conduit.
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Indrani Sen, W. Darrin Clouse, Alexis L. Lauria, Daniel R. Calderon, Peter B. Anderson, Randall R. DeMartino, Todd E. Rasmussen Tags: Original article Source Type: research
More News: Food and Drug Administration (FDA) | Internal Medicine